

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Quetiapine XR 50 mg Extended-Release Tablet (DIN 02395444) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 18, 2017**.

QUETIAPINE FUMARATE

50 MG EXTENDED-RELEASE TABLET

00002407671	SANDOZ QUETIAPINE XRT	SDZ	\$ 0.3950
00002395444	TEVA-QUETIAPINE XR	TEV	\$ 0.3950
00002300184	SEROQUEL XR	AZC	\$ 1.0003

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Propafenone 150 mg Tablet (DIN 02243324) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 21, 2017**.

PROPAFENONE HCL

150 MG TABLET

00002243324	APO-PROPAFENONE	APX	\$ 0.2965
00000603708	RYTHMOL	BGP	\$ 1.2012

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Propafenone 300 mg Tablet (DIN 02243325) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 21, 2017**.

PROPAFENONE HCL

300 MG TABLET

00002243325	APO-PROPAFENONE	APX	\$ 0.5227
00000603716	RYTHMOL	BGP	\$ 2.1172

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Apo-Propafenone 300 mg Tablet (DIN 02243325) manufactured by Apotex Inc. and Rythmol 300 mg Tablet (DIN 00603716) manufactured by BGP Pharma ULC, Mylan-Propafenone 300 mg Tablet (DIN 02245373) manufactured by Mylan Pharmaceuticals ULC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. and BGP Pharma ULC have advised Alberta Blue Cross that the shortages of Apo-Propafenone 300 mg Tablet (DIN 02243325) and Rythmol 300 mg Tablet (DIN 00603716) have been resolved.

As a result, Mylan-Propafenone 300 mg Tablet (DIN 02245373) will no longer be considered a temporary benefit for the *ADBL* after **August 21, 2017**.

Due to the shortages of Mylan-Mirtazapine 15 mg Tablet (DIN 02256096) manufactured by Mylan Pharmaceuticals ULC and pms-Mirtazapine 15 mg Tablet (DIN 02273942) manufactured by Pharmascience Inc., the following products were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*:

DIN	Product description	Manufacturer
02286610	Apo-Mirtazapine 15 mg Tablet	Apotex Inc.
02411695	Auro-Mirtazapine 15 mg Tablet	Auro Pharma Inc.
02250594	Sandoz Mirtazapine 15 mg Tablet	Sandoz Canada Inc.

Mylan Pharmaceuticals ULC has advised Alberta Blue Cross that the shortage of Mylan-Mirtazapine 15 mg Tablet (DIN 02256096) has been resolved.

As a result, the above products will no longer be considered temporary benefits for the *ADBL* after **August 24, 2017**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

